
FDA Proposal for LDTs Risks Serious Consequences
Lab leaders say that the increased level of scrutiny proposed for such tests would be a detriment to innovation and patient care.
Lab leaders say that the increased level of scrutiny proposed for such tests would be a detriment to innovation and patient care.
Genomic sequencing is almost twice as likely to yield a diagnostic result, but lags behind panel testing in speed, cost, and concordance.
Tackling the challenges of “forever chemicals” in the diagnostics industry.
Research reveals that diagnostic error in the US may cause up to 800,000 serious outcomes annually.
A new five-metabolite blood test designed by algorithm could simplify and speed up this challenging diagnosis.